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Despite the prevalence and impact of delirium, its pathophysiology remains unclear. In
order to advance this field of research, robust scientific methodology is required, yet quality
of reporting in this field of research has been highly inconsistent. Delirium biomarker
research poses several challenges, none of which have been documented in the literature
before. The aim of this study was to explore the perspectives of delirium researchers about
key methodological issues in delirium biomarker research.
Methods
Following a Delphi study with delirium experts resulting in 60 recommendations for reporting
delirium biomarker studies, semi-structured interviews with international delirium research-
ers were conducted. Interviews were audio-taped and transcribed verbatim, followed by the-
matic analysis of the qualitative data.
Results
Fifteen participants were interviewed between August and November 2019. Most were
male (n = 12; 75%), clinician researchers (n = 13; 86%), and had more than ten years’ expe-
rience in conducting delirium research (n = 9; 60%). Analysis revealed two major themes
and ten sub-themes, outlining key considerations to advance the field of delirium biomarker
research. The major themes were: 1) Practical and scientific challenges of delirium bio-
marker research: stagnation versus driving improved methods and reporting; and 2) Valuing
delirium research through investment and collaboration.
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Conclusion
Findings identified a range of factors that contribute to the practical and ethical challenges of
conducting delirium biomarker research, which have not previously been explicitly acknowl-
edged or reported. A clear vision for collaborative efforts to enhance research quality for
improved impact was also presented by the delirium researchers. This work complements
the preceding Delphi and together these studies provide an in-depth understanding of what
is needed in the field to inform and improve methods and reporting of delirium biomarker
research.
Introduction
Delirium is a common, serious and complex neurocognitive condition which is often precipi-
tated by medical illness and hospitalisation [1]. The hallmark features of delirium include
changes in attention, awareness and cognition, which variously affect memory, language and
visuospatial ability, orientation and perception [2]. Delirium is associated with multiple
adverse clinical outcomes including high levels of patient and caregiver distress, significant
morbidity and mortality, impairment in activities of daily living, and significant costs to the
healthcare system [3–6].
Delirium prevalence in medical in-patients at admission to hospital has been shown to
range between 10 and 31%, with incidence of new delirium during admission ranging from 3
to 29% [7]. Occurrence rates for delirium per admission ranged between 11 and 42% [7].
Despite the high prevalence and impact of delirium, knowledge of its pathophysiology is
unclear. Current hypotheses include: neuronal ageing, neuroinflammation, oxidative stress,
neuroendocrine dysregulation, and disruption to the circadian rhythm [8]. To date, there has
been remarkably high heterogeneity of delirium biomarker findings addressing these hypothe-
ses. Other challenges to understanding include unsettled questions about whether delirium
represents a single, unified physiological condition or whether there are physiologically dis-
crete subtypes [9]; and ongoing terminological confusion (e.g., delirium vs acute encephalopa-
thy) that drives specialty-specific silos [10]. These high-level issues in the conceptualization of
delirium mean that high quality methodological approaches to biomarker research are critical
to accelerate understanding of delirium pathophysiology in order to lead to potential
therapies.
However, a systematic review of biomarkers in delirium by Amgarth-Duff et al. (2020) [11]
highlighted many quality issues in the reporting of delirium biomarker studies. The overall
low quality of studies has limited the reliability of outcomes, comparability of results, and abil-
ity to synthesise results to develop empirical understanding of delirium pathophysiology. This
poor quality reporting has likely contributed to heterogeneity of findings and biological and
conceptual uncertainty [12]. In response to the need to improve the field of delirium patho-
physiology, a Delphi study was conducted [13] to gather opinions of international experts on
delirium research methodology that resulted in a list of reporting guidelines for future delir-
ium biomarker studies. To supplement these recommendations, interviews with Delphi partic-
ipants and other delirium researchers were then undertaken for an in-depth exploration into
the more complex aspects of biomarker study methods and those with a range of methodologi-
cal options. The consensus and primarily quantitative approach of the Delphi method was not
suited to fully explore these aspects; and, furthermore our present goal was not to obtain rec-
ommendations but rather to understand the key considerations and the reasons underpinning
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them. Therefore, the aim of this study was to explore the perspectives of delirium researchers
about key methodological issues in delirium biomarker research.
Methods
Design
A qualitative study using semi-structured interviews reported in accordance with the Consoli-
dated Criteria for Reporting Qualitative Research (COREQ) [14].
Participants
Eligible participants were researchers, clinicians and basic scientists with experience in delir-
ium research in either humans or animals, including but not restricted to biomarker research.
There was no pre-specified minimum number of years of clinical or research experience; how-
ever, experience in delirium research was required to have been in the last ten years to ensure
recent knowledge of the study topic.
Recruitment
Purposive sampling was employed whereby potential participants were actively selected to
take part [15]. This was achieved by emailing the international delirium researchers who com-
pleted the final round of the Delphi study [13] and other delirium researchers who were not
involved in the Delphi process (n = 27) and asking them to participate in a semi-structured
interview. Delirium researchers were identified by authorship of relevant papers in the field of
delirium, as well as through the lead researchers’ supervisory networks. Snowball sampling
[16] was also employed by asking invitees whether they knew any other relevant persons who
may be interested in participation. Those who indicated willingness to participate were
emailed a participant information sheet and a consent form by the researcher (IAD), which
was required to be signed and sent back prior to the interviews taking place. The participant
information sheet explained the aim of the study: general content to be discussed, anticipated
length of the interview, measures for privacy and confidentiality, and use of data for academic
and research purposes.
Data collection
The interview guide was aligned with the key findings from the earlier Delphi study, while also
allowing other topics to arise [13] (Box 1). The interviews were conducted individually, limit-
ing the influence of group bias. The three key areas explored were: 1) the practical challenges
of conducting delirium biomarker research, and how they can be overcome; 2) how to account
for underlying conditions that are present in many patients with delirium; and 3) the key gaps
Box 1. Interview guide.
1. Delirium is a condition that often occurs in the context of other conditions with similar pathophysiological
processes. What are your thoughts on accounting for co-existing conditions such as cancer in delirium biomarker
studies?
2. Delirium biomarker research poses many practical challenges. In your experience, what some of the key
challenges and some ways to overcome these challenges?
3. Where do you think current biomarker studies are falling short?
4. Do you have any comments on the Delphi statements? (for Delphi participants only)
5. Is there anything else you would like to add before we finish up?
https://doi.org/10.1371/journal.pone.0243254.t001
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and methodological shortcomings in current delirium biomarker studies. Questions were
open-ended and designed to gain an in-depth understanding of the challenges and nuances of
delirium biomarker methodology. The interview guide was piloted with two clinicians who
did not formally take part in an interview. The first had extensive experience in delirium
research, and the other had clinical experience of caring for patients with delirium. The final
interview guide is presented in Box 1.
All interviews were conducted by the lead author (IAD), a female research assistant and
PhD candidate who holds undergraduate and honours qualifications in biomedical science.
IAD has prior interviewing and qualitative analysis experience and an in-depth knowledge of
existing deficiencies in the quality of reporting of delirium biomarker research [11], but no
prior experience of conducting biomarker research. There were no pre-existing relationships
between IAD and participants, although the remaining authors knew some of the participants
through delirium research collaborations, conferences and advocacy networks. IAD had mini-
mal contact with participants from the time of the Delphi through to the interviews, with the
exception of scheduling interviews over email. During telephone interviews, IAD was located in
a private office. Data collection continued until no new information emerged (i.e. data satura-
tion). All interviews were audio recorded and transcribed verbatim in a de-identified format.
Data analysis
A combination of inductive and deductive thematic data analysis [17] was used, as follows:
Deductive thematic analysis. Firstly, key areas identified in Round 1 qualitative analysis of
the modified Delphi study [13] that were too complex to be resolved through a consensus process
(and therefore required a more in-depth analysis) formed the framework for the interview guide.
The lead author (IAD) familiarised herself with the data through the transcription process and
rereading of the final transcripts. Line-by-line coding of the transcripts was conducted, and a cod-
ing tree was developed to elucidate categories. Categories were then collapsed into themes. To
ensure rigour, preliminary themes were independently identified by two researches (IAD and
AH) and refined collaboratively until the final themes and sub-themes were established.
Inductive thematic analysis. Initial data coding was guided by the semi-structured inter-
view questions, with codes and collated data examined for potential sub-themes. Codes were
considered important if they were mentioned more than once. IAD identified preliminary
sub-themes, that were then refined through an iterative process until the final sub-themes
were confirmed by a second researcher (AH).
Data were managed using NVIVO QSR International Pty Ltd. Version 12 software
package.
Trustworthiness of the data
The procedures used in this study were guided by the four general types of trustworthiness in
qualitative research, namely: credibility, transferability, dependability and confirmability.
Trustworthiness of the data was achieved by using purposive sampling, targeting delirium
researchers from a broad range of contexts and countries. The voices of the participants were
widely represented in the quotes which supported the themes and achieved transparently in
the data interpretation. Discussion among co-authors were also used to enhance the trustwor-
thiness of the data analysis.
Ethical considerations
Ethical approval for the interviews was obtained from the University of Technology Human
Research Ethics Committee on 25/01/2019 (HREC ETH18-2673).
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Participant lists were stored on a password protected computer and all participant names
were removed from the data transcripts. Participant confidentiality, privacy and anonymity
were ensured through the allocation of participant ID codes in the transcripts and manuscript.
Data were only accessible to the lead author (IAD) and de-identified data were only shared
with the other authors (MA, AH and GC) for their input into analysis and interpretation.
Findings
Fifteen delirium researchers participated in semi-structured interviews between August and
November 2019. Most participants were male (n = 12;75%), clinician/researchers
(n = 13;86%), had conducted five or more delirium studies (n = 12;80%) and had more than 10
years’ experience in delirium research (n = 9;60%). Participants were from Europe (n = 7),
USA (n = 3), Australia (n = 2), the United Kingdom (UK) (n = 2) and South America (n = 1).
Demographic characteristics of participants are outlined in Table 1. Although participants had
the option of attending a face-to-face or a telephone interview, all participants opted for a tele-
phone interview. Interview duration ranged from 18–80 minutes (mean 37 (±16)).
Thematic analysis resulted in two major themes and ten sub-themes.
1. Practical and scientific challenges of delirium biomarker research: stagnation versus driving
improved methods and reporting
a. Accuracy of diagnostic assessment of delirium
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b. Delirium superimposed on dementia (DSD)
c. Hypothesis driven
d. Limited infrastructure and resource investment
e. Fluctuating nature of delirium means time point of biomarker collection is a crucial
consideration
f. Collecting CSF and imaging in people with delirium
g. Accounting for the complexity/biology of the whole person
h. Standardise delirium biomarker research
2. Valuing delirium research through investment and collaboration:
a. Ethics committee barriers
b. Transdisciplinary collaboration
Practical and scientific challenges of delirium biomarker research:
Stagnation versus driving improved methods and reporting
Participants generally asserted that delirium biomarker research is an extremely difficult and
complex field:
“Yes well the hard thing with this is it is such a complex area and no one actually knows. Peo-
ple know what you have to do but they don’t know how to get there. It’s very difficult. It’s a
very grey area.” (P09)
Some expressed a sense of frustration, stagnation and pessimism in the field, due to the
complexities, challenges and overall uncertainty:
“It’s a difficult field. There is quite a lot of frustration. There are no quick wins. There is no
money coming into the research. I’m not frustrated but I am seeing more difficulties and I am
not sure how to get around them in the long run because ethics committees get more difficult,
money gets scarce, the pressure of clinical work [. . .] I’m such a pessimist! But that’s the way I
see the course of delirium research going in our institution.” (P03)
The need to branch out from siloed investigations and from biomarkers already shown to
be associated with delirium was noted:
“In the 1940’s they found similar things to us now. And it’s like. . . ok let’s move forward! [. . .]
I think there is some element of reconfirming. But I also think there are some elements of split-
ting it into medical delirium, or ICU delirium–it’s important but we have kind of just got so
into that that we have delirium in the cardiac population, delirium in the vascular popula-
tion, and delirium in. . .you know. We have so many of these little pocket categories. We are
reconfirming results because we are interested to see if it’s the same in those populations which
is good but I also think it’s kind of not leading to a huge mass of knowledge [. . .] I think it’s
time we either need to branch out, or use a different method.” (P07)
Delirium biomarker research was perceived to have been a “hype” that has since been dulled
as there have been no “quick wins” (P03), which ironically had become a short-term enterprise:
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“Delirium is something like a hype. Everyone was very excited when the first paper came out–
the one from the States, but it’s gone a bit quiet since then because I think we all realise it’s not
going to be a quick win. So we try to focus on something that is easy to sell.” (P03)
1a. Accuracy of diagnostic assessment of delirium. Participants perceived clinical recog-
nition of delirium to be generally poor, adding to the difficulties of timely diagnosis:
“The downside is that I’m seeing a very small percentage of people that need to be seen.
Because they’re not recognized. People think ‘oh they’re old’ or ‘they have dementia’ without
even knowing if they have dementia. Or ‘oh they have been in intensive care, of course they
are going to be confused.’ So outside of the geriatric medicine it’s quite challenging.” (P13)
It appeared that there were conflicting processes for delirium assessment and that most
identification of delirium for research purposes relied on clinicians’ identification of delirium,
rather than researcher assessment. This was seen as problematic because participants felt they
could not rely on the accuracy of clinicians’ recognition and assessment of delirium:
“The first is how to classify patients having delirium or not. Because we have to define whether
the patient has delirium and sometimes when we are assessing the patient, he has no delirium,
but we have previous reports from the nursing staff or from clinical records that the day before
he was on delirium. So it’s difficult to classify this type of patient.” (P10)
Participants readily acknowledged the difficulty of precisely defining delirium, noting that
it is a syndrome that varies from person to person:
“Because delirium is a set of signs and symptoms and it’s not necessarily a diagnosis that you
make with histopathology or with very specific lab tests. So you may not detect delirium until
a certain time point but that doesn’t mean the brain wasn’t injured prior to that time point,
so there is a lot of uncertainty about when delirium started and when it’s resolved–these make
it very challenging.” (P12)
Others highlighted uncertainties with the classification of sub-syndromal delirium, noting
that these individuals are often placed in the ‘control group’ (i.e. no delirium) in delirium bio-
marker studies:
“I think when you use the binary of delirium–the yes/no it is because there can be symptoms
present- like sub-syndromal delirium–and they’re not going to sell it by the full-blown delir-
ium. [. . .] I think understanding the symptom burden at the time of the biomarker being
drawn is really important [. . .] maybe they are fluctuating and have some disorganised think-
ing but they don’t have inattention—so technically they can’t qualify as having delirium but
some can certainly argue that there definitely is some brain dysfunction going on. Therefore, if
they do not have a proper diagnosis of delirium at the time of blood draw then they would be
categorised as non-delirious. So it’s introducing a lot of noise into the data.” (P07)
1b. Delirium superimposed on dementia (DSD). DSD was a significant challenge men-
tioned by several participants, and the importance of adjusting for dementia in all delirium
biomarker studies was highlighted:
“If you are doing biomarker studies in delirium you really need to have a picture of the
dementia status of the patient both because dementia is the strongest risk factor for delirium
PLOS ONE Challenges in delirium biomarker research
PLOS ONE | https://doi.org/10.1371/journal.pone.0243254 April 7, 2021 7 / 19
and because dementia also impacts on the biomarkers that you want to measure and some-
times the relation is in the opposite direction [. . .] So if you don’t adjust for dementia in your
analysis then they will level one another out.” (P11)
The need to have multiple control groups in delirium biomarker studies to understand
which biomarkers are affected by dementia was identified:
“Well that’s why we are doing this study. . .to distinguish. We are classifying patients into four
groups. So we have patients who are totally normal, with no delirium and no dementia. And
then we have patients with dementia and delirium, then dementia without delirium and also
patients with no dementia and [with] delirium. So we can compare the effects of delirium
superimposed on dementia.” (P10)
1c. Hypothesis driven. The importance of taking into consideration the underlying biol-
ogy of delirium by testing for a hypothesis was discussed. It was noted that “there isn’t any
thought going into it” (P15) including about which biomarkers were being studied and why:
“People are doing these studies with no eye on the biology. I mean I find it really frustrating
[. . .] Everyone is going–‘Ok we will just get this kit, put the 27 chemokines or cytokines on
there, bang them on’, but there isn’t any thought going into it. For me, it’s a huge problem
because no one is actually testing a hypothesis. I think that not enough biomarker studies
have a real clear guiding principle, and that is a hypothesis that they are testing. Because if
you are testing a hypothesis then you have to think about what it would take to provide sup-
port to the hypothesis, or to refute the hypothesis. I just feel that no one states a clear hypothe-
sis, no one is studying a hypothesis so we just have very weak associations.” (P15)
One participant noted that authors often concluded that there was a ‘dysregulation’ in
inflammatory markers, without taking into account any priori hypothesis. The need to clearly
state and define a hypothesis was perceived as one reason for weak associations in delirium
biomarker studies:
“And it means that if they do a panel of 27 markers and only 2 of them change, then they can
just say ‘this provides evidence for inflammatory dysregulation in delirium’–and that’s of no
value whatsoever, because if you look at 27 things then statistically at least one of them will
change by chance! And therefore you are going to find something and if it goes up or down
and you don’t really care which, because you can say ‘dysregulation’ either way and that
means you’re going into a paper with zero hypothesis, you’re just saying throw it at the wall
[. . .] I find it very infuriating- those studies are not contributing to the knowledge of delir-
ium.” (P15)
1d. Limited infrastructure and resource investment. The difficulties of conducting bio-
marker research without appropriate infrastructure was perceived as a potential barrier to rig-
orous delirium biomarker research:
“I guess it’s difficult to do collection of samples for biomarker research or any kind when you
don’t have the infrastructure. We have only just got a minus 80 freezer so basically if you were
in a place that is not an academic centre and they haven’t given you a shelf for research sam-
ples that can be tricky [. . .] It’s not impossible but it’s obviously useful to do research outside
of academic.” (P6)
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Whereas another participant believed that there are fundamental principles of conducting
and reporting delirium biomarker studies that should be adhered to if the results are to inform
the field, regardless of funding.
“I guess it’s a resource argument. But I disagree, because if we aren’t following some sort of
guidelines then we are really doing our patients a disservice because we are not going to make
any progress [. . .] Whenever you draw a biomarker you should follow the same steps regard-
less of whether you have funding or not. You’re not saying what assay they should use, you’re
saying when you write up your findings you need to share which assay and how they did it. I
don’t see how you need money for that.” (P07)
1e. Fluctuating nature of delirium means time point of biomarker collection is a crucial
consideration. Several participants acknowledged the great challenge with ensuring the right
timing of biomarker collection due to the fluctuating nature of delirium:
“They’re difficult. Essentially because delirium is normally fixed pretty quickly around the
hospital environment, especially around geriatrics. There is a small window of finding those
patients.” (P01)
Some highlighted the need for longitudinal samples to track delirium over time:
“And then you need to follow the patient, ideally several times a day to be safe. Because delir-
ium episodes can be for maybe some hours, and it can develop during the weekend or during
the night and if you don’t have a plan for how you are going to assess this information then
you will lose it and falsely classify the patient as non-delirious.” (P11)
However, other participants thought that longitudinal sampling was not always feasible:
“You need to make a system where you still are able to pick up the CSF the day it comes and
that is very hard unless you want to employ a person to be at the hospital 24/7—it will be
extremely expensive.” (P11)
1f. Collecting CSF and imaging in people with delirium. CSF was considered the ‘gold
standard’ in delirium biomarker research, due to the proximity to the brain, providing an
advantage over blood. Despite most participants believing that CSF collection posed too many
practical challenges, others emphasised the need for more CSF sampling, noting that it was
more likely to directly reflect brain processes during delirium:
“So the first problem is, in my opinion, you really need CSF. You cannot do delirium bio-
marker studies in blood. Well you can, but there are not so many good candidates for bio-
markers in blood that give you good information about the brain.” (P11)
Yet most participants spoke about the difficulties of CSF collection via lumbar puncture,
namely its invasiveness and burden on patients:
“CSF is not easy to get hold of because you need to do a lumbar puncture which is considered
invasive.” (P11)
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Similarly, despite the great opportunity that neuroimaging has to offer, several participants
focused on the practical challenges of imaging studies and the difficulties associated with
undertaking a PET scan when a patient is agitated:
“Yes well you can’t do a PET during the delirium, you would have to wait for the delirium to
be resolved so that you can coach him through a PET session.” (P03)
For this reason, there was a perceived bias towards hypoactive subtypes in PET studies,
resulting in unrepresentative samples:
“Yes that’s part of the other problems. We tend to have much more of a bias for the hypoactive
delirium [in imaging studies].” (P01)
1g. Accounting for the complexity/biology of the person as a whole. Majority of partici-
pants commented on the need to create a homogenous and “clean” cohort, acknowledging
that people with delirium, particularly in the ICU, often had several underlying conditions
affecting the results:
“I think you want to have a really clean cohort and not too many comorbidities so if you want
to come up with a biomarker that you want to associate with the disease process [. . .] we need
cleaner cohorts so we can isolate a biomarker that is specific to delirium.” (P09)
In contrast, other participants concurred that the next step to broaden delirium biomarker
studies is to biomarkers across several settings:
“Well repeating it in more ICU patients might not be that helpful. For instance, it’s a lot easier
for me to do it in the ICU because that’s where a lot of my research lies. If we really find some-
thing that hits then you—start looking at that biomarker in other populations. And if it’s hit-
ting across multiple [populations] then that gives you a lot more confidence that it’s actually
specific to delirium, right?” (P02)
One participant argued that “existing brain state is going to be the key determinant of
whether those acute changes are enough to trigger delirium” (P15), therefore emphasising the
need to obtain true baseline measurements. Not having a precise baseline was considered a
major shortcoming in delirium biomarker studies:
“I think a key practical challenge with delirium is that we don’t have baselines [. . .] that’s par-
ticularly important for somebody with my mindset because I think your brain state before
delirium is the major predictor of who will get delirium and how badly they will be affected.
So the severity of the acute insult is obviously a major determinant, but who is vulnerable to
having delirium in those situations—we learn about that by having a baseline.” (P15)
The surgical space was considered the best setting for conducting delirium biomarker
research with respect to having true baseline measurements:
“I would say the best cohort is probably peri-operative and post-operative because you know
exactly what kind of injury is happening and when it is happening and you can have a bio-
marker before the injury and then you can have the biomarker after the insult.” (P09)
PLOS ONE Challenges in delirium biomarker research
PLOS ONE | https://doi.org/10.1371/journal.pone.0243254 April 7, 2021 10 / 19
Some participants asserted that patients in this setting generally had less co-existing condi-
tions that can influence the results and therefore can provide a more accurate depiction of the
specific biomarkers for delirium:
“You should need to take patients perhaps in surgery. So the hip fracture patient group is a possible
patient group because they break their hips and you can distinguish these biomarkers that come
from the hip fracture and those that come from the delirium so this is a very interesting population.
Normally you don’t have sepsis. Normally you don’t have cancer or something like that.” (P08)
On the other hand, others emphasised that the prevalence of delirium in this group was
much lower, which subsequently introduces a selection bias:
“If you do cognitive studies in elective surgery patients you will always have a selection bias.
So if we look at the patients who participate in our studies they are cognitive at baseline, pre
operatively, they are much better. . .three points lower . . .than if you take a random sample of
the patients we treat here and that puts you in an awkward position. So there is a methodolog-
ical flaw right from the start.” (P03)
The heterogeneity of delirium causation was considered a major challenge which varied
from person to person. The common approach of relying on clinical identification of delirium
left people uncertain:
“Delirium is so multifactorial so if you take an ICU patient, you have so many possible patho-
physiological mechanisms that will lead to delirium [. . .] That’s why it’s so heterogeneous and
why it will never have a magic bullet or an overall approach to the problem. It’s different in every
patient. In every patient, it’s his personal mix of mechanisms to go into delirium. That makes
therapy so difficult because there are so many underlying causes [. . .] so there are several mecha-
nisms that lead to delirium that makes standardisation in studies nearly impossible.” (P03)
When asked about accounting for underlying conditions present in people with delirium,
participants acknowledged that, as a whole, delirium researchers have thus far inadequately
tackled this issue:
“Nobody is doing it [accounting for underlying conditions] and nobody knows what to do
about it so it’s really good you are writing this. It will give some ideas to people.” (P09)
1h. Standardisation of delirium biomarker research. Participants reflected on the qual-
ity of current delirium biomarker research and highlighted the issue of poorly reported and/or
conducted delirium biomarker studies:
“We don’t do a very good job on the side of reporting and reporting that precision so it’s rather
messy and a lot of the time unable to tell whether the person doing the biomarkers whether
they were drawn before or during the delirium.” (P07)
Participants asserted the need for reporting guidelines, highlighting that often researchers
merely replicated procedures of others in the field without considering best practice methods:
“I think our field is missing a metric or a standard to follow. So you just end up doing what
your institution or other studies typically do and that’s how you report it.” (P07)
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Using the same protocols for assay procedures was considered important for standardisa-
tion, as well as for the potential to combine samples for larger delirium biomarker studies:
“We should try to use similar protocols at different centres so it’s possible to combine samples
[. . .] You can also standardise the way you handle your samples after you collect them–just
basic things like using the same tubes because some biomarkers that you want to analyse they
can adhere. . . if you don’t use the correct material to collect the CSF then the proteins can
adhere to the surface then you can’t trust your results.” (P11)
Valuing delirium research through investment and collaboration
2a. Ethics committee barriers. Many participants shared a frustration towards ethics
committees’ restrictions in relation to delirium biomarker studies, highlighting it as a notable
barrier to progressing the field:
“We are very restrictive for supporting this kind of research. For example, you won’t get
patients with a very severe dementia and delirium because most of the ethical committees
won’t let family members give proxy consent.’ (P08)
A reason for the strict restrictions was the perception of ethics committees that patients did
not directly profit from being involved in a delirium biomarker study:
“We have a general problem with perception of doing research on patients. They think we use
them like guinea pigs. Particularly with delirium research where you don’t have a personal
profit. It is different if you are in the oncology and you are coming up with a treatment regi-
men—there you have a potential profit for yourself. In delirium research you don’t and they
are very reluctant to say yes and go along with that.” (P03)
There was a perception that ethics committees considered people with delirium too vulner-
able to be included in research; hence, introducing a selection bias whereby cohorts in these
studies often consisted of people with lower risk of delirium:
“Essentially our ethics committees are getting more difficult. Many patients who have a high
risk of delirium are a cognitively impaired at baseline so they fall into the category of vulnera-
ble group of patients which makes it difficult to approach them. Then we have the problem
that the . . . if you approach, you will get the good ones with too low rates of delirium.” (P03)
A pragmatic solution to this barrier was to append the biomarker study onto an already exist-
ing trial, alleviating the hurdles of obtaining ethical approval for delirium biomarker studies:
“Linking to some sort of ongoing trial that is enrolling people for another reason [. . .] So I
think linking on to randomised controlled trials or big observational cohorts, whatever they’re
doing, getting funding and adding it on something that is co-existing is a lot easier.” (R02)
In contrast, one participant took a long-term approach, and disagreed with tagging the bio-
marker component onto an existing study. They argued that in order to conduct robust delir-
ium biomarker research, the studies must be “bespoke” and original:
“If you want to do a really good biomarker study, or really good pathophysiology work then
sometimes you just can’t build that on the back of routine clinical care. They have to be
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bespoke studies where you have to go the extra mile [. . .] You have to write up a protocol
that’s more involved, that asks more of the patient and carers [. . .] It’s one of those things,
that if you really want to advance the research, then you need to do a real research study. And
by real, I mean bespoke. That’s not being critical of the opportunistic studies, but sometimes if
you want to answer the hard questions, you have to do the hard studies.” (P15)
2b. Transdisciplinary collaboration. Participants described a number of areas where cur-
rent delirium biomarker studies were falling short. They acknowledged that current studies
were predominantly conducted by clinicians:
“I think delirium is a relatively young field and it’s been driven primarily by clinicians which
is great because they’re really invested or embedded in the health system next to the patient so
you have that really rich clinical representation. But the down side is that they just aren’t nec-
essarily trained very strong methodologically.” (P07)
The importance of collaboration between clinicians and scientists to improve the science of
delirium biomarker studies was highlighted by most:
“I am not sure whether the basic scientists work on this topic. It’s more that delirium clinicians
work on this type of research [. . .] I think it’s about integrating these people into the study.”
(P08)
Discussion
This study of delirium researchers’ perspectives about the key methodological challenges in
the conduct and reporting of delirium biomarker research sheds light on the current state of
the scientific field. Findings identified a range of factors that contribute to the challenges of
conducting delirium biomarker research and the risk of the field not accelerating efforts,
which have not previously been explicitly acknowledged or reported. It provides the most in-
depth exploration of these challenges to date, and some important insights into how to address
the many practical, scientific and quality issues in research into delirium pathophysiology.
Practical and scientific challenges of delirium biomarker research:
Stagnation versus driving improved methods and reporting
Overall, researchers in this study concurred that delirium biomarker research is in practical
terms an extremely difficult and complex field. A minority took a long-term view, whereas
many reported taking short-term approaches, even as they acknowledged that the latter was
unlikely to advance scientific knowledge of delirium. Although the practical difficulties and
complexities of delirium biomarker research was a common finding, some participants also
provided clues and suggestions as to how some issues may be addressed.
The issue of delirium under-recognition and misdiagnosis by clinicians, which has been
extensively studied and reported as occurring in 21% - 79% of cases across settings [18–20]. It
appears from the present study that reliance on clinical identification of delirium, as opposed
to researcher assessment, has contributed to much uncertainty about whether delirium was
indeed present, or not, at the time of biomarker collection. This finding flags the urgent need
for more systematic and reliable processes for delirium identification in research into its bio-
markers, which will require greater involvement of researchers and reporting of diagnostic
quality. Furthermore, there are conflicting methods in how the features of delirium are
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assessed for research purposes. The difficulties with classifying delirium sub-types was also
highlighted. The ability to distinguish between the different etiologic subtypes will be critical
to elucidate delirium pathophysiology and to develop effective treatments.
There was congruence in the researchers’ views that accounting for co-existing conditions
in delirium was important but extremely challenging, and divergent views about how to
resolve the question. Most were uncertain about how to tackle this topic, and yet addressing
this uncertainty in a united way is crucial to advancing the field of research. Delirium superim-
posed on dementia (DSD) was considered a key challenge by researchers, who noted the
importance of adjusting for dementia in delirium biomarker studies. Delirium is a risk factor
for dementia, and is associated with worsening severity in individuals with existing dementia
[21]. The prevalence of DSD in community and hospitalised settings is well documented and
ranges between 22% and 89% in people aged 65 and older [22]. When dementia and delirium
co-exist, it is difficult to ascertain whether the observed changes in a particular biomarker
were related to the delirium, or confounded by the underlying dementia [23]. Animal models
of delirium during dementia have been developed, which suggest that prior synaptic loss and
microglial priming are predisposing factors for acute cognitive impairment induced by sys-
temic inflammation [24]. Although this model is highly promising, further validation in more
studies is required. There is also an urgent need to characterise these two conditions biologi-
cally and clinically in human studies. Including multiple control/comparator groups would
help to elucidate the distinctions.
A challenge identified in this study was the acuity, fluctuating course and often brief dura-
tion of delirium. These factors make precise determination of its onset and resolution
extremely difficult; and yet research recruitment and precision in the timing of biomarker col-
lection is crucial in delirium biomarker studies to accurately capture the delirium episode [25].
Furthermore, pathophysiological processes may differ in active delirium compared to those
individuals who are not yet delirious. A standardised way of determining delirium resolution
is also required, as there is currently no consensus on the definition of delirium resolution
[26].
The proximity of CSF to the brain makes it a good target for studying the pathophysiology
of central nervous system conditions. Obtaining CSF for research purposes however has
numerous practical challenges. Most delirium researchers discussed the burden of CSF collec-
tion by lumbar puncture (LP), and referred to the procedure as “invasive”. Although there is
no literature on the experience of adults undergoing LP, there has been much research in chil-
dren and adolescents. One study demonstrated that 75% of parents/caregivers of children who
were scheduled to undergo an LP did not consent because of the fear of complications [27].
One proposed solution to this barrier is to improve the quality and person-centeredness of
information given to potential participants, to increase their understanding of the proposed
research. A recent scoping review reported that many older people were willing to participate
in research in the event of reduced decision-making capacity from a desire to contribute to sci-
entific knowledge, although less so in studies with higher risks or burdens for them [28].
Reducing study risks and burdens, as well as improved communication processes with poten-
tial participants and proxies, are therefore crucial. For example, simplified information and
consent forms using lay language that avoids medical jargon as well as extended discussions
can lead to improvements in participant understanding and appreciation of study information
[29, 30].
Neuroimaging is another method that has sparked interest in attempts to understand the
neural correlates of delirium. Neuroimaging is routinely used in clinical practice; however,
there are still very few studies on neuroimaging in delirium, which likely reflects the practical
and ethical challenges involved in imaging patients with hyperactive delirium. Delirium
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researchers in this study expressed concerns about the practical challenges of getting a person
who is agitated to lie still in a PET scanner. One solution is to ensure patients are accompanied
by a relative or carer to reassure them prior to and during the scans, as was effectively enacted
in another study [31]. Although imaging studies are deemed to be extremely difficult, large
samples which adjust for confounding factors (for example, pre-existing cognitive
impairment) are needed, as well as long-term vision and planning of research programs to
facilitate the advancement of adequately powered studies [32].
The need to account for and understand the complexity and biology of the whole person
was highlighted as a gap in current delirium biomarker studies. A key limitation of many pre-
vious studies in acutely admitted patients was the lack of objective cognitive testing at baseline,
therefore making it difficult to know if any observed changes in biomarkers were related to the
delirium, or were confounded by underlying conditions. Many researchers suggested that
future delirium biomarker studies focus on the surgical setting, where patients have a true pre-
operative baseline. The limitation of this approach is that delirium is a multifactorial condi-
tion, which almost always occurs in the context of other physiological processes that need to
be accounted for in study participants.
This study confirmed that standardised methods in the form of reporting guidelines for
delirium biomarker research are urgently required, as was initially identified in a previous sys-
tematic review [11]. Inadequate and/or unclear reporting of methodological processes can lead
to discrepancies in results, which may be misleading and potentially detrimental to the
research [33]. Overall, reporting guidelines are deemed necessary to promote studies that are
standardised and reliable. This statement is consistent with other studies that reported
improvements in reporting rigor when reporting guidelines such as the CONSORT (Consoli-
dated Standards of Reporting Trials) [34] were adopted. Many journals have taken steps to
improve the quality of the research articles that they publish by requiring the use of reporting
guidelines, although research shows there is still room for improvement [35]. Having global
standardised guidelines to conduct delirium biomarker research with similar reference stan-
dards will help to improve the quality of reporting within studies and thereby increase oppor-
tunities for syntheses across studies.
Valuing delirium research through investment and collaboration
There are several ethical challenges to conducting research in patient populations at higher
risk of harm, such as delirious patients who are often considered too vulnerable for research
participation [36]. There is an ethical tension in delirium research; balancing the need to pro-
tect this more vulnerable population with upholding their rights to be included in research
and the need to improve medical care [25]. This study confirmed that ethics committee inter-
pretation of current research regulations when applied to delirium research are perhaps
exceedingly stringent. This is driven by several factors: patients are unlikely to directly profit
from participating in a delirium biomarker study, concerns about potential harms to a vulner-
able population, perceived burden of specimen collection and the quality of informed consent.
Those with impaired capacity are often either excluded from research or less frequently
recruited, to circumvent the challenges of tailoring methods and study measures [28]. How-
ever, this evasion leads to unrepresentative study populations and thereby limits external valid-
ity of the research [25, 37].
Common motivations of older people to participate in research in the context of impaired
decision-making include altruism, potential personal benefits, and a desire to contribute to sci-
entific knowledge [28]. Greater consumer (e.g. people who have previously experienced delir-
ium or their caregivers) input into delirium biomarker study development would help to
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ensure improved value proposition and communication by researchers to ethics committees
and potential participants/proxies so they can better weigh the rewards/risks of delirium stud-
ies might help to overcome some of the barriers identified in this study.
The common approach of relying on the clinical identification of delirium within bio-
marker research should be replaced with a more rigorous process. Such a process could be elu-
cidated by clinicians, scientists and researchers working in a more united way to improve
methods in delirium biomarker research. This issue was identified in this study by the frequent
acknowledgement that currently delirium biomarker research is predominantly conducted by
clinicians with minimal background in basic science. To address these gaps, multi-institutional
collaborative efforts are needed to generate valid, reproducible and generalisable findings in
delirium biomarker research. The Successful Aging after Elective Surgery (SAGES) [32] pro-
gram is one example of a collaborative project aiming to achieve research rigour and results
that would likely be unattainable by investigators working independently.
Implications for research
Delirium is a major clinical and public health concern, and robust scientific research on patho-
physiological mechanisms are urgently needed. Developing reporting guidelines is an essential
step to improving methodological and reporting quality in delirium biomarker research.
Increased international, multisite and transdisciplinary collaboration, along with concept
development workshops focused on methodology of conducing delirium biomarker research
at international delirium society meetings, would enable improvements in the field. Further-
more, better explanation of study rationales to ethics committees, and involvement of consum-
ers, could help in alleviating some of the challenges identified in this study. Despite many
studies seeking to better understand the pathophysiology of delirium, these barriers continue
to impede high-quality delirium biomarker research. Raising awareness and changing practice
and culture offer the multidimensional effort that is needed to progress this fundamental field
of delirium research. Details regarding our recommendations for future research are given in
Table 2.
Strengths and limitations
A key strength of this study was the inclusion of participants from multiple disciplines and
countries who were actively involved in delirium research, allowing data saturation to be
reached. Secondly, the qualitative method allowed for an in-depth exploration into the reasons
underpinning the participant views, giving clearer guidance of the specific areas for advance-
ment in the field.
Participants were purposefully sampled in order to facilitate in-depth exploration delirium
researchers’ perspectives, and so these findings are likely to be specific to the challenges of
delirium biomarker research, rather than be transferable to biomarker research more gener-
ally. We are unsure if the predominance of male and clinician researcher participants is repre-
sentative of the field, or had any particular influence on the findings of the study; however, this
is worth noting as a potential limitation. Another limitation was that almost all participants in
the study were from high-income countries.
Conclusion
Findings of this qualitative study identified a range of factors that contribute to the challenges
of conducting delirium biomarker research, which have not previously been explicitly
acknowledged or reported. These factors all contribute to the overall quality of research in this
field. Findings complemented the preceding systematic review and Delphi survey, and
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together these studies will inform strategies to improve the methods and reporting of delirium
biomarker research. A concerted effort is now required to standardise and strengthen several
aspects of the conduct and reporting of delirium biomarker studies, in order to advance this
highly promising but yet to deliver scientific field of research.
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Table 2. Recommendations for future research.
Interview theme Recommendation
Practical and scientific challenges of delirium biomarker research: stagnation versus driving improved methods and
reporting
Accuracy of diagnostic assessment of delirium Development of a reference standard for the diagnosis of
delirium is needed.
Delirium superimposed on dementia (DSD) In acutely admitted patients, assessments on cognitive decline
should be used to assess dementia status. The use of multiple
control/comparator groups could help elucidate the
distinctions.
Hypothesis driven Pre-defined hypotheses need to be supported by a strong
biological underpinning.
Limited infrastructure and resource investment Standardising protocols to allow for future collaborations
between laboratories is essential.
Fluctuating nature of delirium means time point of
biomarker collection is a crucial consideration
A standardised way of determining delirium resolution is
required.
Collecting CSF and imaging in people with delirium Person-centeredness is essential to increase participants
understanding of the proposed research.
Accounting for the complexity/biology of the whole
person
In elective studies, patients should undergo objective
cognitive testing to obtain a true baseline before biomarker
sampling.
Standardise delirium biomarker research Reporting guidelines specific to delirium biomarker studies
are needed.
Valuing delirium research through investment and collaboration
Ethics committee barriers Greater consumer input into delirium biomarker study
development would help to ensure improved value
proposition and communication by researchers to ethical
committees and potential participants.
Transdisciplinary collaboration Ongoing international, multisite and transdisciplinary
collaboration, including concept development workshops on
delirium biomarker research is essential.
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